Johnson & Johnson’s Risperdal Woes Roll On
By Jason Enzler
The hits keep coming for Johnson & Johnson. On August 30, several state attorneys general announced that they have agreed to a $181 million settlement with Janssen Pharmaceuticals, a J & J subsidiary, regarding charges that the company was illegally promoting its antipsychotic drugs Risperdal and Invega. Click here
for a press release from New York. The settlement, involving 36 states and the...